Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1471-2466
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis ; volume:21 ; number:1 ; day:11 ; month:12 ; year:2021 ; pages:1-11 ; date:12.2021
BMC pulmonary medicine ; 21, Heft 1 (11.12.2021), 1-11, 12.2021

Urheber
Finnerty, James Patrick
Ponnuswamy, Aravind
Dutta, Prosjenjit
Abdelaziz, Ammar
Kamil, Hafiz
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12890-021-01783-1
URN
urn:nbn:de:101:1-2022021819370167736912
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
16.08.2024, 10:49 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Finnerty, James Patrick
  • Ponnuswamy, Aravind
  • Dutta, Prosjenjit
  • Abdelaziz, Ammar
  • Kamil, Hafiz
  • SpringerLink (Online service)

Ähnliche Objekte (12)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)

MiR-608 overexpression in idiopathic pulmonary fibrosis (IPF)

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America

Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)

Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)

Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema

Acute exacerbations of COPD versus IPF in patients with combined pulmonary fibrosis and emphysema

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry

Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis

Nintedanib (Ofev) : IPF-Therapie: Frühstart erwünscht

Nintedanib (Ofev) : IPF-Therapie: Frühstart erwünscht

Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)

Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF)

Verbundene Objekte